西达本胺、雷利度胺和地塞米松治疗多发性骨髓瘤的有效性与安全性研究  

Research on Efficacy and Safety of Sidabelamide, Ralidomide and Dexamethasone in Treatment of Multiple Myeloma

作　　者：罗自勉 尹亚飞 谭小军 刘康 晁志 Luo Zi-mian;Yin Ya-fei;Tan Xiao-jun;Liu Kang;Chao Zhi(Department of Hematology,Xiangtan Central Hospital,Xiangtan 411100,Hunan Province,China;Department of Reproductive and Genetic Center,Xiangtan Central Hospital,Xiangtan 411100,Hunan Province,China;Blood Laboratory,Xiangtan Central Hospital,Xiangtan 411100,Hunan Province,China)

机构地区：[1]湘潭市中心医院血液科,湖南湘潭411100 [2]湘潭市中心医院生殖与遗传中心,湖南湘潭411100 [3]湘潭市中心医院血液实验室,湖南湘潭411100

出　　处：《中国社区医师》2022年第28期49-51,共3页Chinese Community Doctors

基　　金：湖南省科技创新计划项目(编号:2018SK52108)。

摘　　要：目的:研究西达本胺、雷利度胺和地塞米松治疗多发性骨髓瘤的有效性与安全性。方法:选择2019年8月-2020年8月湘潭市中心医院收治的84例多发性骨髓瘤患者作为研究对象,随机分为观察组和对照组,各42例,对照组使用雷利度胺和地塞米松治疗,观察组在对照组基础上加用西达本胺,比较两组患者临床治疗效果,血红蛋白、血肌酐、血清M蛋白、骨髓浆细胞水平,不良反应发生率。结果:观察组临床治疗有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗前,两组血红蛋白、血肌酐、血清M蛋白、骨髓浆细胞水平比较,差异无统计学意义(P>0.05);治疗后,观察组血红蛋白、血肌酐、血清M蛋白以及骨髓浆细胞水平显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:西达本胺、雷利度胺、地塞米松治疗多发性骨髓瘤对各项临床症状具有缓解作用,值得临床应用。Objective: To study the efficacy and safety of sidabelamide, ralidomide and dexamethasone in the treatment of multiple myeloma. Methods: A total of 84 patients with multiple myeloma treated in Xiangtan Central Hospital from August 2019 to August2020 were selected as the study subjects. They were randomly divided into observation group and control group, with 42 cases in each group. The control group was treated with ralidomide and dexamethasone;On the basis of the control group, the observation group was treated with sidabelamide. The clinical treatment effect, the levels of hemoglobin, serum creatinine, serum M protein,medullary plasma cells, and the incidence of adverse reactions were compared between the two groups. Results: The clinical treatment effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no significant difference in the levels of hemoglobin, serum creatinine,serum M protein and medullary plasma cells between the two groups(P>0.05). After treatment, the levels of hemoglobin, serum creatinine, serum M protein and medullary plasma cells in the observation group were significantly lower than those in the control group, with statistically significant differences(P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion: Sidabelamide, ralidomide and dexamethasone in the treatment of multiple myeloma can alleviate various clinical symptoms, which is worthy of clinical application.

关 键 词：西达本胺 雷利度胺 地塞米松 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]